Novartis ends NN622 deal with Novo Nordisk
Novartis has decided not to continue the joint development andcommercialization of Novo-Nordisk's dual-acting sensitiser, NN622 (DRF-2725), which is currently being developed as a treatment for non-insulin dependent type 2 diabetes, on the grounds that the compound did not fit its profile for a drug of this type.
The agreement was reached earlier this year (Marketletter July 30), but Novartis has now returned all rights to commercialize the compound in the USA, Canada and Mexico to Novo Nordisk, which will continue with the initiation of the Phase III program. Novo Nordisk note that the discontinuation of the agreement with Novartis will not impact its expectations for the 2001 financial year. Novartis also licenses an insulin sensitizer from India's Dr Reddy (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze